A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 1

Conditions: Healthy

Treatments: Drug: Furosemide; Drug: MK-2828; Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT07431866

2828-005

Details and patient eligibility

About

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF.

The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Enrollment: 39 estimated patients

Sex: All

Ages: 24 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m^2

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Has a history of cancer (malignancy)

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

39 participants in 2 patient groups

Rosuvastatin + MK-2828

Experimental group

Description:

Participants receive rosuvastatin and MK-2828 orally.

Treatment:

Drug: Rosuvastatin

Drug: MK-2828

Furosemide + MK-2828

Experimental group

Description:

Participants receive furosemide and MK-2828 orally.

Treatment:

Drug: MK-2828

Drug: Furosemide